DAY 4 - Wednesday, May 7
BLOG FROM ARVO
Editor's Blog: Posters more than paper
The digital world is always moving into our lives in some form and fashion. So it should not surprise anyone that the traditional poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) meeting would one day deliver clinical research with a digital component. That day has arrived! » MORE
|
|
DRUG THERAPY
Using suprachoroidal drug delivery
Local delivery of pharmacotherapy to the eye has long been used for anterior segment disease but various routes for delivery have also been investigated, said Timothy Olsen, MD. » MORE
|
|
NSAIDs offer potential hope for DR, AMD
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well recognized as potent agents as they block all downstream prostaglandins, have a long history of safety and efficacy, and fare well in extended-release formulations. Recently, there has been a growing body of evidence showing that they have potential in treating cystoid macular edema, said Stephen Kim, MD. » MORE
|
|
CLINICAL DIAGNOSIS
New tool to evaluate dark adaptation
Almost 70% of patients with age-related macular degeneration (AMD) are unaware of their disease until vision loss has occurred, said Gregory R. Jackson, PhD. » MORE
|
|
Genes identify potential risk for AMD
Patients with 2 CFH risk alleles and no ARMS2 risk alleles would be better served by something other than the Age-Related Eye Disease Study (AREDS) formulation, according to Carl C. Awh, MD. » MORE
|
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
| |
|
 Top Tweets
|
|
We welcome your feedback!
Please send your comments to:
Mark L. Dlugoss
Group Content Director
Advanstar Eye Health Group
[email protected] |
|
|
